Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold at Benchmark

Share on StockTwits

Benchmark downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a report published on Thursday, BenzingaRatingsTable reports.

A number of other research firms also recently commented on REGN. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $585.00 to $635.00 and gave the stock a neutral rating in a report on Thursday, August 6th. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, August 15th. Goldman Sachs Group boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $800.00 in a report on Wednesday, August 5th. Wells Fargo & Co upgraded shares of Regeneron Pharmaceuticals from an equal weight rating to an overweight rating and boosted their target price for the stock from $559.00 to $734.00 in a report on Tuesday, May 26th. Finally, Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $400.00 to $624.00 and gave the stock a neutral rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $584.46.

Shares of REGN stock traded down $7.89 during midday trading on Thursday, reaching $609.00. 9,709 shares of the company were exchanged, compared to its average volume of 608,291. Regeneron Pharmaceuticals has a 12 month low of $271.37 and a 12 month high of $664.64. The company has a market cap of $66.99 billion, a P/E ratio of 23.75, a PEG ratio of 1.66 and a beta of 0.56. The company’s 50 day moving average price is $626.16 and its two-hundred day moving average price is $541.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $1.57. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the previous year, the firm earned $6.02 EPS. Regeneron Pharmaceuticals’s revenue was up 23.7% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 28.16 earnings per share for the current year.

In related news, Director P Roy Vagelos sold 33,460 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $602.94, for a total transaction of $20,174,372.40. Following the completion of the sale, the director now owns 234,649 shares of the company’s stock, valued at $141,479,268.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Robert E. Landry sold 696 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $654.46, for a total value of $455,504.16. Following the sale, the chief financial officer now directly owns 23,973 shares of the company’s stock, valued at approximately $15,689,369.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 85,283 shares of company stock valued at $52,173,606. Insiders own 11.84% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. United Capital Financial Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 35.4% during the first quarter. United Capital Financial Advisers LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $586,000 after buying an additional 314 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 1.4% during the first quarter. Mutual of America Capital Management LLC now owns 10,881 shares of the biopharmaceutical company’s stock valued at $5,313,000 after buying an additional 148 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Regeneron Pharmaceuticals by 4.5% during the second quarter. Ameritas Investment Partners Inc. now owns 3,608 shares of the biopharmaceutical company’s stock valued at $2,250,000 after buying an additional 154 shares in the last quarter. Anderson Fisher LLC raised its holdings in Regeneron Pharmaceuticals by 116.7% during the first quarter. Anderson Fisher LLC now owns 117 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 63 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 4,727.4% during the first quarter. Oppenheimer Asset Management Inc. now owns 23,220 shares of the biopharmaceutical company’s stock valued at $11,338,000 after buying an additional 22,739 shares in the last quarter. Institutional investors own 68.07% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: What is the accumulation/distribution indicator?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply